Search Clinical Trials
Sponsor Condition of Interest |
---|
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
National Cancer Institute (NCI)
Low Grade Astrocytoma
Low Grade Glioma
Metastatic Low Grade Astrocytoma
Metastatic Low Grade Glioma
This phase III trial compares the effect of selumetinib versus the standard of care
treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed
or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality
called BRAFV600E mutation and is not1 expand
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it. Type: Interventional Start Date: Jan 2020 |
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis1
National Cancer Institute (NCI)
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
This phase III trial studies if selumetinib works just as well as the standard treatment
with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma
(LGG), and to see if selumetinib is better than CV in improving vision in subjects with
LGG of the optic pathway (vision nerve1 expand
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine. Type: Interventional Start Date: Jan 2020 |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refrac1
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Histiocytic Sarcoma
Juvenile Xanthogranuloma
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well
treatment that is directed by genetic testing works in pediatric patients with solid
tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at
least one line of standard systemic thera1 expand
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. Type: Interventional Start Date: Jul 2017 |
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Columbia University
Mitochondrial Disorders
Mitochondrial Genetic Disorders
Mitochondrial Diseases
Disorder of Mitochondrial Respiratory Chain Complexes
Deletion and Duplication of Mitochondrial DNA
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact
registry and tissue biorepository for patients with mitochondrial disorders. expand
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders. Type: Observational Start Date: Dec 2010 |
Natural History of Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
Pain Crisis
This study is not a treatment protocol and no experimental treatments are involved. Study
participants may be seen as needed for clinical, translational and basic research
studies, or as medically indicated. Subjects will receive their general medical care
outside the NIH and will be seen at our cl1 expand
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated. Subjects will receive their general medical care outside the NIH and will be seen at our clinic or at CNHS with varying frequency. Subjects may be seen for multiple visits. Subjects may be asked to return for additional testing as needed. Clinical care for patients with sickle cell disease will be provided as appropriate through the Sickle Cell Clinic and the inpatient clinical center. Type: Observational Start Date: Apr 2004 |
Rare Group Problem Management+
Children's National Research Institute
Anxiety
Depressive Symptoms
Post-traumatic Stress Disorder
Problems Psychosocial
Participants are being asked to be in the study if they are the parent or legal guardian
of a child (>1 year or <18 years old) with a rare condition.
The group based psychoeducational intervention is called Rare Group Problem Management
Plus.
Rare Group PM Plus may help adults with practical and1 expand
Participants are being asked to be in the study if they are the parent or legal guardian of a child (>1 year or <18 years old) with a rare condition. The group based psychoeducational intervention is called Rare Group Problem Management Plus. Rare Group PM Plus may help adults with practical and emotional problems. It is a group program (there will be other men or women with similar problems) It happens once a week for 5 weeks (each session lasts 90 minutes) Participants will complete assessments before they start Rare Group PM+. Participants will also complete the same assessments within a few weeks of completing Rare Group PM+. Assessments should only take one hour. Study visits are by Telemedicine. Participants will need a smart phone or tablet. If they do not have a smart phone or tablet, the study team will help with this. Participants will not receive any materials or money or medication. Type: Interventional Start Date: Feb 2024 |
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Tra1
Arkansas Children's Hospital Research Institute
Hematopoietic Cell Transplant
Solid Organ Transplant
Respiratory Viral Infection
The participants are being asked to take part in this clinical trial, a type of research
study, because the participants are scheduled to receive or have recently received a
hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).
Primary Objective
To determine if pre-transplant scr1 expand
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: - To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors. - To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors . Type: Observational Start Date: Dec 2022 |
PAINED: Project Addressing INequities in the Emergency Department
Children's National Research Institute
Pain
Appendicitis
Bias, Racial
Fractures, Bone
Racial and ethnic inequities in health care quality have been described across a broad
range of clinical settings, patient populations, and outcomes. Our overarching goal is to
eradicate health care inequities through evidence-based interventions. The objectives of
this proposal are to develop and1 expand
Racial and ethnic inequities in health care quality have been described across a broad range of clinical settings, patient populations, and outcomes. Our overarching goal is to eradicate health care inequities through evidence-based interventions. The objectives of this proposal are to develop and test the impact of two interventions on overcoming clinician implicit bias and mitigating inequities in the management of pain among children seeking care in the emergency department for the treatment of appendicitis or long bone fractures. Type: Interventional Start Date: Feb 2023 |
Physiologic Measure of VIPN
Children's National Research Institute
Chemotherapy-induced Peripheral Neuropathy
The purpose of this study is the development of a physiologic endpoint using a novel
technology that would provide an objective, easy to use and more sensitive assessment of
VIPN in children and adolescents. The ability to more easily detect and monitor VIPN,
even before it is clinically evident, w1 expand
The purpose of this study is the development of a physiologic endpoint using a novel technology that would provide an objective, easy to use and more sensitive assessment of VIPN in children and adolescents. The ability to more easily detect and monitor VIPN, even before it is clinically evident, would facilitate optimizing the dosing of vincristine for maximal disease response while minimizing the risk of lifelong functional deficits affecting quality of life. This approach would also enable the development of specific therapies to minimize or eliminate the occurrence of VIPN in children and adolescents. This is a single site study that aims to develop a novel device to evaluate and characterize vincristine-induced neuropathic pain. The investigators will enroll patients with ALL following the Delayed Intensification (DI) phase of treatment. At each study visit, the investigators will evaluate the nPRD as well as the TNS-PV. The nPRD will inform the neuropathy index which will be used to compare to the TNS-PV. We anticipate a correlation between the two. Type: Observational Start Date: Sep 2021 |
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastati1
Ascentage Pharma Group Inc.
Unresectable or Metastatic Melanoma or Advanced Solid Tumors
Melanoma
Uveal Melanoma
P53 Mutation
MDM2 Gene Mutation
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary
efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with
pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with
metastatic melanomas or advanced solid tumors. Our hy1 expand
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy. Type: Interventional Start Date: Aug 2018 |
Eliminating Monitor Overuse Trial (EMO Trial)
Children's Hospital of Philadelphia
Bronchiolitis Acute Viral
The purpose of this study is to identify the optimal deimplementation strategies for an
overused practice: continuous pulse oximetry monitoring of children hospitalized with
bronchiolitis who are not receiving supplemental oxygen. expand
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen. Type: Interventional Start Date: Dec 2021 |
Nasotracheal Intubation With VL vs DL in Infants Trial
Children's Hospital of Philadelphia
Intubation Complication
Intubation; Difficult or Failed
Hypoxia
Hypoxemia
Anesthesia Intubation Complication
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants
(NasoVISI) Trial is a prospective randomized multicenter study. The study will be
conducted at 8 centers in the United States. It is expected that approximately 700
subjects enrolled to product 670 evaluable subjec1 expand
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants (NasoVISI) Trial is a prospective randomized multicenter study. The study will be conducted at 8 centers in the United States. It is expected that approximately 700 subjects enrolled to product 670 evaluable subjects.The randomization is 1:1 naso tracheal intubation with the Storz C-Mac Video Videolaryngoscopy (VL) or the Standard Direct Laryngoscope (DL). The primary objective is to compare the nasotracheal intubation (NTI) first attempt success rate using VL vs. DL in infants 0-365 days of age presenting for cardiothoracic surgery and cardiac catheterizations. Type: Interventional Start Date: Jun 2022 |
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intri1
National Cancer Institute (NCI)
Anaplastic Astrocytoma
Anaplastic Astrocytoma, Not Otherwise Specified
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Glioblastoma
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in
combination with standard radiation therapy in treating children and young adults with
newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a
genetic change called H3 K27M mu1 expand
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG. Type: Interventional Start Date: May 2022 |
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BL1
NYU Langone Health
AVB - Atrioventricular Block
Fetal AVB
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the
2nd trimester of pregnancy in an otherwise normally developing heart, is almost
universally associated with maternal anti-Ro autoantibodies and results in death in a
fifth of cases. To date treatment of 3° AVB h1 expand
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition period of several hours in which incomplete block (2° AVB) may be successfully treated avoiding fully advanced irreversible 3° AVB. To optimize the likelihood of timely detection of the transition period this study comprises three steps: 1) to risk stratify for high titer anti-Ro antibodies, which are necessary but not sufficient to develop fetal AVB; 2) to empower mothers to identify 2° AVB by using fetal heart rate and rhythm monitoring (FHRM) at home, and 3) to rapidly treat mothers who detect an abnormality by monitoring with an urgent echocardiogram that confirms 2° AVB with the hope of reversing 2° AVB before it becomes permanent (3° AVB). In addition, it will be determined if FHRM reduces the need for weekly echoes. Although mothers with low titer anti-Ro will not be continued in Step 2 and therefore not followed by FHRM, birth ECGs will be collected to confirm that low titer antibodies do not confer risk. It is anticipated that this study will provide an evidenced based surveillance strategy for those mothers at high risk of having a child with 3° AVB. Type: Interventional Start Date: Aug 2020 |
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ep1
Pediatric Brain Tumor Consortium
Medulloblastoma
Glioblastoma Multiforme
Anaplastic Astrocytoma
High-grade Astrocytoma NOS
Anaplastic Oligodendroglioma
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually
thought of as ways to prevent diseases, vaccines can also be used to treat cancer.
SurVaxM is designed to tell the body's immune system to look for tumor cells that express
a protein called survivin and destroy1 expand
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. The survivin protein can be found on up to 95% of glioblastomas and other types of cancer but is not found in normal cells. If the body's immune system knows to destroy cells that express survivin, it may help to control tumor growth and recurrence. SurVaxM will be mixed with Montanide ISA 51 before it is given. Montanide ISA 51 is an ingredient that helps create a stronger immune response in people, which helps the vaccine work better. This study has two phases: Priming and Maintenance. During the Priming Phase, patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection (a shot under the skin) at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At the same time that patients get the SurVaxM/Montanide ISA 51 injection, they will also get a second subcutaneous injection of a medicine called sargramostim. Sargramostim is given close to the SurVaxM//Montanide ISA 51 injection and works to stimulate the immune system to help the SurVaxM/Montanide ISA 51 work more effectively. If a patient completes the Priming Phase without severe side effects and his or her disease stays the same or improves, he or she can continue to the Maintenance Phase. During the Maintenance Phase, the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years. After a patient finishes the study treatment, the doctor and study team will continue to follow his/her condition and watch for side effects up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be seen in clinic every 3 months during the follow-up period. Type: Interventional Start Date: Jul 2022 |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuro1
Children's Oncology Group
Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
This research trial studies biomarkers in tumor tissue samples from patients with newly
diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from
patients with cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer. expand
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Type: Observational Start Date: Nov 2000 |
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Children's Oncology Group
Childhood Malignant Neoplasm
This clinical trial studies cancer survivors to identify those who are at increased risk
of developing late-occurring complications after undergoing treatment for childhood
cancer. A patient's genes may affect the risk of developing complications, such as
congestive heart failure, avascular necrosi1 expand
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. Type: Observational Start Date: Mar 2004 |
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignan1
Therapeutic Advances in Childhood Leukemia Consortium
Hematologic Malignancy
AML
ALL
BPDCN
MDS
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to
target CD123 has been approved for treatment in pediatric and adult patients with blastic
plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of
this novel agent in pediatric patie1 expand
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study. Type: Interventional Start Date: Nov 2022 |
Systemic Biomarkers of Brain Injury From Hyperammonemia
Children's National Research Institute
Urea Cycle Disorder
Organic Acidemia
Maple Syrup Urine Disease
Glutaric Acidemia I
Fatty Acid Oxidation Disorder
Ammonia is a waste product of protein and amino acid catabolism and is also a potent
neurotoxin. High blood ammonia levels on the brain can manifest as cytotoxic brain edema
and vascular compromise leading to intellectual and developmental disabilities. The
following aims are proposed:
Aim 1 of th1 expand
Ammonia is a waste product of protein and amino acid catabolism and is also a potent neurotoxin. High blood ammonia levels on the brain can manifest as cytotoxic brain edema and vascular compromise leading to intellectual and developmental disabilities. The following aims are proposed: Aim 1 of this study will be to determine the chronology of biomarkers of brain injury in response to a hyperammonemic (HA) brain insult in patients with an inherited hyperammonemic disorder. Aim 2 will be to determine if S100B, NSE, and UCHL1 are altered in patients with two other inborn errors of metabolism, Maple Syrup Urine Disease (MSUD) and Glutaric Acidemia (GA1). Type: Observational Start Date: Jul 2020 |
Augmented Reality For MRI-Guided Interventions
Children's National Research Institute
Infections
Pain
Diagnosis
Image Guided Needle Biopsy
The purpose of this study is to determine feasibility and safety of using an augmented
reality system in patients undergoing MRI-Guided needle procedures. expand
The purpose of this study is to determine feasibility and safety of using an augmented reality system in patients undergoing MRI-Guided needle procedures. Type: Interventional Start Date: Feb 2024 |
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epilept1
Neurocrine Biosciences
SCN8A Developmental and Epileptic Encephalopathy Syndrome
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of
NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and
Epileptic Encephalopathy Syndrome (SCN8A-DEE). expand
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE). Type: Interventional Start Date: Jan 2022 |
Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: the1
George Washington University
HIV
AIDS
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort
that will describe clinical outcomes, and improve the quality of care for outpatients
with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in
Washington, DC. expand
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for outpatients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in Washington, DC. Type: Observational Start Date: Jan 2011 |
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocyte1
Catherine Bollard
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
This Phase I dose-escalation trial is designed to evaluate the safety of administering
rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to
HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment of high-risk
or relapsed or refractory hematopoi1 expand
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment of high-risk or relapsed or refractory hematopoietic malignancies. In addition to safety, this study will also evaluate if event-free survival (EFS) is improved with TAA-T administration at six months after HSCT for patients with high risk AML and MDS (Arm C). Type: Interventional Start Date: Jan 2015 |
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Day1
Otsuka Pharmaceutical Development & Commercialization, Inc.
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
The primary objective of this study is to evaluate the effect of tolvaptan on the need
for renal replacement therapy in pediatric subjects with autosomal recessive polycystic
kidney disease (ARPKD) expand
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD) Type: Interventional Start Date: Jul 2022 |
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Nationwide Children's Hospital
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized,
placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe
hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome
(MODS). expand
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS). Type: Interventional Start Date: Jun 2022 |
- Previous
- Next